Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

OTHER BALANCE SHEET COMPONENTS

OTHER BALANCE SHEET COMPONENTS

12 Months Ended

Dec. 31, 2021

OTHER BALANCE SHEET COMPONENTS

OTHER BALANCE SHEET COMPONENTS

9. OTHER BALANCE SHEET COMPONENTS

Property and equipment consist of the following (in thousands):


	December 31,
	2021		2020
Laboratory equipment	$	12,154	$	11,957
Computer and software		1,783		1,783
Furniture and equipment		2,107		1,793
Fixed assets in progress		691		819
Total property and equipment		16,735		16,352
Less accumulated depreciation and amortization		(14,551)		(13,676)
Property and equipment, net	$	2,184	$	2,676

Total depreciation and amortization expense were $1.2 million, $0.7 million and $0.7 million for the year ended December 31, 2021, 2020 and 2019, respectively. Depreciation and amortization expense for the year ended December 31, 2021 include an impairment charge of $0.1 million. See “Note 14 – Restructuring Charges” for related discussions.

Other accrued liabilities consist of the following (in thousands):


	December 31,
	2021		2020
Revenue reserves	$	5,898	$	4,577
Accrued expenses		3,580		3,661
Refund liability		2,017		1,488
Income tax payable		605		—
Accrued professional fees		204		1,017
Accrued interest payable		387		271
Total	$	12,691	$	11,014

Revenue reserves includes chargebacks, discounts, and fees, as well as government and other rebates. Refund liability relates to allowance for sales returns. See “Note 3 – Revenues” for related details.